covering socal

.

erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.

treatment delays are also causing needless anxiety and distress to patients as well as putting lives at serious risk..

.
.
.. november 2015  (24).
advertisement